Non-Hodgkin Lymphoma | Specialty

The OncLive Non-Hodgkin Lymphoma condition center page is a comprehensive resource for clinical news and expert insights on various types of non-Hodgkin lymphoma, including diffuse large B-cell lymphoma, follicular lymphoma, chronic lymphocytic leukemia, and more. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in non-Hodgkin lymphoma.

Upfront Therapy Strategies in Follicular Lymphoma

January 5th 2018

Follicular Lymphoma: Outcomes After Immunochemotherapy

January 5th 2018

Practical Considerations for Subcutaneous Rituximab

December 29th 2017

Subcutaneous Rituximab: A New Approach to Treating FL

December 29th 2017

Highlights from ASH 2017: Mantle Cell Lymphoma

December 23rd 2017

Investigational Treatment in Mantle Cell Lymphoma

December 23rd 2017

Future Therapy: Bruton's TKI Containing Combinations in MCL

December 23rd 2017

Allogeneic Transplantation in Mantle Cell Lymphoma

December 23rd 2017

Acalabrutinib in Relapsed Mantle Cell Lymphoma

December 23rd 2017

Ibrutinib in Relapsed Mantle Cell Lymphoma

December 23rd 2017

Understanding Relapse in Mantle Cell Lymphoma

December 23rd 2017

Maintenance Therapy in Mantle Cell Lymphoma

December 23rd 2017

Considerations for Autologous Stem Cell Transplantation

December 23rd 2017

Induction Therapy for Mantle Cell Lymphoma

December 23rd 2017

The Watch-and-Wait Approach in Mantle Cell Lymphoma

December 23rd 2017

The Value of MIPI and Ki-67 in Mantle Cell Lymphoma

December 23rd 2017

Considerations for Diagnosing Mantle Cell Lymphoma

December 23rd 2017

Classifying Mantle Cell Lymphoma

December 23rd 2017

Rituximab/Lenalidomide Regimen Misses Endpoint in Phase III Follicular Lymphoma Study

December 22nd 2017

The combination of rituximab and lenalidomide followed by maintenance therapy with the same regimen did not improve response nor progression-free survival compared with rituximab and chemotherapy with rituximab maintenance for patients with previously untreated follicular lymphoma.

Update Shows Frontline Bendamustine/Rituximab Improves TTNT in NHL

December 15th 2017

Ten-year follow-up results from the StiL NHL1 study showed that frontline bendamustine (Treanda) plus rituximab (Rituxan) improved time-to-next-treatment compared with CHOP-R in patients with indolent lymphomas.